Differential Expression Analysis of Blood MicroRNA in Identifying Potential Genes Relevant to Alzheimer’s Disease Pathogenesis, Using an Integrated Bioinformatics and Machine Learning Approach
Source abstract
Abstract
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by cognitive and functional impairment. Recent research has focused on the deregulation of microRNAs (miRNAs) in blood as the potential biomarkers for AD. As such, a differential expression analysis of miRNAs was conducted in this study using an integrated framework that utilized the advantages of statistical and machine learning approaches. Three miRNA candidates that showed the strongest significance and correlation with each other, namely hsa-miR-6501-5p, hsa-miR-4433b-5p, and hsa-miR-143-3p, were identified. The roles and functions of the identified differentiated miRNA candidates with AD development were verified by predicting their target mRNAs, and their networks of interaction in AD pathogenesis were investigated. Pathway analysis showed that the pathways involved in contributing to the development of AD included oxidative phosphorylation, mitochondrial dysfunction, and calcium-mediated signalling. This study supports evidence that the miRNA expression changes in AD and indicates the need for further study in this area.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: MicroRNA in disease regulation · Circular RNAs in diseases · Cancer-related molecular mechanisms research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Bioinformatics Programme, Institute of Biological Sciences, Faculty of Science, Universiti Malaya, Kuala Lumpur 50603, Malaysia
Department of Pathology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia
Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia
Centre of Research in System Biology, Structural, Bioinformatics and Human Digital Imaging (CRYSTAL), Universiti Malaya, Kuala Lumpur 50603, Malaysia
Funding
Fundamental Research Grant Scheme (FRGS), Ministry of Higher Education Malaysia · UM International Collaboration Grant
References (80)
Show source-provided references
1. Wolk, D.A., and Dickerson, B.C. (2016). Clinical Features and Diagnosis of Alzheimer Disease, UpToDate.
2. MicroRNAs as Potential Orchestrators of Alzheimer’s Disease-Related Pathologies: Insights on Current Status and Future Possibilities10.3389/fnagi.2021.743573 ↗
3. Miya Shaik, M., Tamargo, I.A., Abubakar, M.B., Kamal, M.A., Greig, N.H., and Gan, S.H. (2018). The role of microRNAs in Alzheimer’s disease and their therapeutic potentials. Genes, 9.10.3390/genes9040174 ↗
4. MicroRNA-4722-5p and microRNA-615-3p serve as potential biomarkers for Alzheimer’s disease10.3892/etm.2022.11166 ↗
5. Plasma microRNA vary in association with the progression of Alzheimer’s disease
6. Zhang, W., Zhang, G., and Gao, S. (Neurologia, 2021). The potential diagnostic accuracy of circulating microRNAs for Alzheimer’s disease: A meta-analysis, Neurologia, in press.10.1016/j.nrl.2021.06.001 ↗
7. The promise of microRNA-based therapies in Alzheimer’s disease: Challenges and perspectives10.1186/s13024-021-00496-7 ↗
8. MicroRNAs in Alzheimer’s disease: Diagnostic markers or therapeutic agents?10.3389/fphar.2019.00665 ↗
9. Differential blood miRNA expression in brain amyloid imaging-defined Alzheimer’s disease and controls
10. Are circulating microRNAs peripheral biomarkers for Alzheimer’s disease?10.1016/j.bbadis.2016.06.001 ↗
11. MicroRNAs in Alzheimer’s disease: Potential diagnostic markers and therapeutic targets10.1016/j.biopha.2022.112681 ↗
12. Micro RNA as a potential blood-based epigenetic biomarker for Alzheimer’s disease10.1016/j.clinbiochem.2018.05.020 ↗
13. Differential expression of microRNAs in Alzheimer’s disease brain, blood, and cerebrospinal fluid10.1016/j.jalz.2019.06.4952 ↗
14. Mahendran, N., Vincent, P.D.R., Srinivasan, K., and Chang, C.-Y. (2021). Improving the classification of alzheimer’s disease using hybrid gene selection pipeline and deep learning. Front. Genet., 12.10.3389/fgene.2021.784814 ↗
15. A review on omics-based biomarkers discovery for Alzheimer’s disease from the bioinformatics perspectives: Statistical approach vs machine learning approach10.1016/j.compbiomed.2021.104947 ↗
16. Robles, J.A., Qureshi, S.E., Stephen, S.J., Wilson, S.R., Burden, C.J., and Taylor, J.M. (2012). Efficient experimental design and analysis strategies for the detection of differential expression using RNA-Sequencing. BMC Genom., 13.10.1186/1471-2164-13-484 ↗
17. Identification of differentially expressed microRNAs across the developing human brain10.1038/mp.2013.93 ↗
18. Machine learning for effectively avoiding overfitting is a crucial strategy for the genetic prediction of polygenic psychiatric phenotypes10.1038/s41398-020-00957-5 ↗
19. Benchmark of filter methods for feature selection in high-dimensional gene expression survival data10.1093/bib/bbab354 ↗
20. Prediction of differentially expressed microRNAs in blood as potential biomarkers for Alzheimer’s disease by meta-analysis and adaptive boosting ensemble learning10.1186/s13195-021-00862-z ↗
21. Adaptive boosting-based computational model for predicting potential miRNA-disease associations10.1093/bioinformatics/btz297 ↗
22. Lugli, G., Cohen, A.M., Bennett, D.A., Shah, R.C., Fields, C.J., Hernandez, A.G., and Smalheiser, N.R. (2015). Plasma exosomal miRNAs in persons with and without Alzheimer disease: Altered expression and prospects for biomarkers. PLoS ONE, 10.10.1371/journal.pone.0139233 ↗
23. Machine learning to detect Alzheimer’s disease from circulating non-coding RNAs10.1016/j.gpb.2019.09.004 ↗
24. Cutadapt removes adapter sequences from high-throughput sequencing reads10.14806/ej.17.1.200 ↗
25. Fast gapped-read alignment with Bowtie 210.1038/nmeth.1923 ↗
26. Comparison of analysis tools for miRNA high throughput sequencing using nerve crush as a model10.3389/fgene.2013.00020 ↗
27. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data10.1093/bioinformatics/btp616 ↗
28. mlr3: A modern object-oriented machine learning framework in R10.21105/joss.01903 ↗
29. MSVM-RFE: Extensions of SVM-RFE for multiclass gene selection on DNA microarray data10.1093/bioinformatics/btm036 ↗
30. Kohonen, T. (2012). Self-Organizing Maps, Springer Science & Business Media.
31. Anke, Z., Xinjian, Q., and Guojian, C. (2014, January 15–16). Clustering analysis of gene data based on PCA and SOM neural networks. Proceedings of the 2014 Fifth International Conference on Intelligent Systems Design and Engineering Applications, Hunan, China.10.1109/ISDEA.2014.70 ↗
32. Self-and super-organizing maps in R: The Kohonen package10.18637/jss.v021.i05 ↗
33. Principal component analysis10.1039/C3AY41907J ↗
34. Principal component analysis: A review and recent developments10.1098/rsta.2015.0202 ↗
35. DIANA-microT web server v5. 0: Service integration into miRNA functional analysis workflows10.1093/nar/gkt393 ↗
36. DIANA-miRPath v3. 0: Deciphering microRNA function with experimental support10.1093/nar/gkv403 ↗
37. KEGG: Kyoto encyclopedia of genes and genomes10.1093/nar/28.1.27 ↗
38. Gene ontology analysis for RNA-seq: Accounting for selection bias10.1186/gb-2010-11-2-r14 ↗
39. Cytoscape: A software environment for integrated models of biomolecular interaction networks10.1101/gr.1239303 ↗
40. Human microRNA-4433 (hsa-miR-4443) Targets 18 Genes to be a Risk Factor of Neurodegenerative Diseases10.2174/1567205019666220805120303 ↗
41. Sproviero, D., Gagliardi, S., Zucca, S., Arigoni, M., Giannini, M., Garofalo, M., Olivero, M., Dell’Orco, M., Pansarasa, O., and Bernuzzi, S. (2021). Different miRNA profiles in plasma derived small and large extracellular vesicles from patients with neurodegenerative diseases. Int. J. Mol. Sci., 22.10.3390/ijms22052737 ↗
42. Peña-Bautista, C., Álvarez-Sánchez, L., Cañada-Martínez, A.J., Baquero, M., and Cháfer-Pericás, C. (2021). Epigenomics and Lipidomics Integration in Alzheimer Disease: Pathways Involved in Early Stages. Biomedicines, 9.10.3390/biomedicines9121812 ↗
43. Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment10.1038/mp.2014.127 ↗
44. Serum microRNA miR-501-3p as a potential biomarker related to the progression of Alzheimer’s disease10.1186/s40478-017-0414-z ↗
45. Wang, L., Shui, X., Mei, Y., Xia, Y., Lan, G., Hu, L., Zhang, M., Gan, C.-L., Li, R., and Tian, Y. (2022). miR-143-3p Inhibits Aberrant Tau Phosphorylation and Amyloidogenic Processing of APP by Directly Targeting DAPK1 in Alzheimer’s Disease. Int. J. Mol. Sci., 23.10.3390/ijms23147992 ↗
46. Mitochondrial ATP synthase deficiency due to a mutation in the ATP5E gene for the F1 ε subunit10.1093/hmg/ddq254 ↗
47. Mitochondrial genes are altered in blood early in Alzheimer’s disease10.1016/j.neurobiolaging.2016.12.029 ↗
48. Network-based identification of genetic factors in ageing, lifestyle and type 2 diabetes that influence to the progression of Alzheimer’s disease10.1016/j.imu.2020.100309 ↗
49. Fine mapping of calcineurin (PPP3CA) gene reveals novel alternative splicing patterns, association of 5′ UTR trinucleotide repeat with addiction vulnerability, and differential isoform expression in Alzheimer’s disease10.3109/10826084.2010.482449 ↗
50. Don’t forget astrocytes when targeting Alzheimer’s disease10.1111/bph.14568 ↗
51. Increased APOE ε4 expression is associated with the difference in Alzheimer’s disease risk from diverse ancestral backgrounds10.1002/alz.12287 ↗
52. Integrative genomics approach identifies conserved transcriptomic networks in Alzheimer’s disease10.1093/hmg/ddaa182 ↗
53. Conditional inactivation of nicastrin restricts amyloid deposition in an Alzheimer’s disease mouse model10.1111/acel.12131 ↗
54. A strategy focused on MAPT, APP, NCSTN and BACE1 to build blood classifiers for Alzheimer׳ s disease10.1016/j.jtbi.2015.03.039 ↗
55. Potential involvement of GRIN2B encoding the NMDA receptor subunit NR2B in the spectrum of Alzheimer’s disease
56. EIF2AK3 variants in Dutch patients with Alzheimer’s disease10.1016/j.neurobiolaging.2018.08.016 ↗
57. An exploratory study on STX6, MOBP, MAPT, and EIF2AK3 and late-onset Alzheimer’s disease10.1016/j.neurobiolaging.2012.10.004 ↗
58. Machine learning compensates fold-change method and highlights oxidative phosphorylation in the brain transcriptome of Alzheimer’s disease10.1038/s41598-021-93085-z ↗
59. Mitochondrial DNA damage in a mouse model of Alzheimer’s disease decreases amyloid beta plaque formation10.1016/j.neurobiolaging.2013.04.014 ↗
60. Identification of PSEN1 and PSEN2 Gene Variants and Clinical Findings with the Literature
61. Presence of a mutation in PSEN1 or PSEN2 gene is associated with an impaired brain endothelial cell phenotype in vitro10.1186/s12987-020-00235-y ↗
62. MKP-1 reduces Aβ generation and alleviates cognitive impairments in Alzheimer’s disease models10.1038/s41392-019-0091-4 ↗
63. A selective p38α/β MAPK inhibitor alleviates neuropathology and cognitive impairment, and modulates microglia function in 5XFAD mouse
64. Dauricine attenuates spatial memory impairment and alzheimer-like pathologies by enhancing mitochondrial function in a mouse model of Alzheimer’s disease10.3389/fcell.2020.624339 ↗
65. Quantitative profiling brain proteomes revealed mitochondrial dysfunction in Alzheimer’s disease10.1186/s13041-019-0430-y ↗
66. Polymorphisms within RYR3 gene are associated with risk and age at onset of hypertension, diabetes, and Alzheimer’s disease10.1093/ajh/hpy046 ↗
67. Ryanodine receptors: Physiological function and deregulation in Alzheimer disease10.1186/1750-1326-9-21 ↗
68. Up-regulation of the type 3 ryanodine receptor is neuroprotective in the TgCRND8 mouse model of Alzheimer’s disease10.1111/j.1471-4159.2009.06487.x ↗
69. Role of BACE1 in Alzheimer’s synaptic function10.1186/s40035-017-0093-5 ↗
70. BACE1 role in Alzheimer’s disease and other dementias: From the theory to the practice10.4103/1673-5374.313041 ↗
71. The case for low-level BACE1 inhibition for the prevention of Alzheimer disease10.1038/s41582-021-00545-1 ↗
72. Genetic association of the cytochrome c oxidase-related genes with Alzheimer’s disease in Han Chinese10.1038/s41386-018-0144-3 ↗
73. Platelet cytochrome oxidase and citrate synthase activities in APOE ε4 carrier and non-carrier Alzheimer’s disease patients10.1016/j.redox.2017.04.010 ↗
74. Oxidative phosphorylation is dysregulated within the basocortical circuit in a 6-month old mouse model of down syndrome and alzheimer’s disease10.3389/fnagi.2021.707950 ↗
75. Mitochondrial dysfunction and oxidative stress in Alzheimer’s disease10.3389/fnagi.2021.617588 ↗
76. Bell, S.M., Barnes, K., De Marco, M., Shaw, P.J., Ferraiuolo, L., Blackburn, D.J., Venneri, A., and Mortiboys, H. (2021). Mitochondrial dysfunction in Alzheimer’s disease: A biomarker of the future?. Biomedicines, 9.10.3390/biomedicines9010063 ↗
77. Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: Recent advances10.1186/s13024-020-00376-6 ↗
78. Unraveling Aβ-mediated multi-pathway calcium dynamics in astrocytes: Implications for Alzheimer’s disease treatment from simulations10.3389/fphys.2021.767892 ↗
79. Dysregulation of intracellular calcium signaling in Alzheimer’s disease10.1089/ars.2018.7506 ↗
80. Calcium hypothesis of Alzheimer’s disease and brain aging: A framework for integrating new evidence into a comprehensive theory of pathogenesis10.1016/j.jalz.2016.12.006 ↗